PLP-Tesa & Ipamorelin Blend – 10mg/5mg (15mg Total) | Research Blend

This blend combines PLP-Tesa, a 44-amino acid GHRH analog, with Ipamorelin, a selective pentapeptide growth hormone secretagogue, in a single lyophilized vial at a 10mg/5mg ratio. The combination is designed to engage two distinct, complementary receptor pathways involved in growth hormone regulation within one research formulation.

Mechanism & Research Rationale:

PLP-Tesa is a synthetic GHRH analog featuring a trans-3-hexenoic acid modification at the N-terminus, which enhances stability and resistance to enzymatic degradation compared to endogenous GHRH. It is studied for its interactions with the GHRH receptor pathway and associated pituitary signaling. Ipamorelin, by contrast, is a selective GHRP studied for its activity at the ghrelin receptor (GHS-R1a). The rationale for combining them stems from research examining how GHRH and GHRP pathways interact through distinct receptors and intracellular signaling cascades, allowing the two compounds to serve as a model for studying complementary signaling mechanisms simultaneously.

Key Research Areas:

• Growth Hormone Signaling Dynamics — Research models examine the interaction between GHRH and ghrelin receptor pathways and their respective roles in growth hormone-related signaling.
• GHRH & Ghrelin Receptor Research — PLP-Tesa and Ipamorelin provide a research model for examining two distinct receptor systems and their associated molecular signaling pathways.
• Selective Receptor Research — Ipamorelin’s research profile includes investigation of its receptor selectivity and associated molecular signaling characteristics relative to other GHRP-class compounds.
• Pituitary Somatotroph Signaling — PLP-Tesa engages the GHRH receptor’s Gs-protein/adenylyl cyclase/cAMP/PKA pathway, while Ipamorelin engages the ghrelin receptor’s Gq-protein/calcium/PKC pathway — two mechanistically distinct downstream cascades studied in relation to pituitary signaling.

Product Specifications:

• PLP-Tesa: 10mg | 44 amino acids | Trans-3-hexenoic acid N-terminal modification
• Ipamorelin: 5mg | Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ | 5 amino acids
• 15mg total lyophilized powder per vial
• ≥99% purity, third-party COA available (mass spectrometry recommended)
• Store refrigerated (2–8°C); protect from light and moisture

For laboratory and research use only. Not intended for human or animal consumption, diagnostic, or therapeutic use. Not a drug, dietary supplement, or cosmetic. Not FDA-approved.